Latest Macrolide antibiotics Stories
CHAPEL HILL, N.C., May 13 /PRNewswire/ -- Cempra Pharmaceuticals today announced the schedule of poster presentations on its next-generation macrolide, CEM-101, at the American Thoracic Society (ATS) 2010 International Conference in New Orleans, Louisiana, on May 14 to 19, 2010. Both posters will be presented during the poster session entitled "C41 Emerging Pharmacology for Chronic Obstructive Pulmonary Disease: Mechanisms and Outcomes" scheduled for 8:15 a.m.
Children and adolescents with cystic fibrosis who received the antibiotic azithromycin did not experience improved lung function, compared to patients who received placebo.
CHAPEL HILL, N.C., Apr.
CHICAGO, March 11 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc.
CHENGDU, China, Oct.
CHICAGO, June 2 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc.
CHICAGO, May 29 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), announced today that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the June 2, 2009 Anti-Infective Drugs Advisory Committee (AIDAC) meeting.
CHICAGO, Dec. 3 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that the U.S.
Long-term use of an antibiotic may reduce the frequency of exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD), but the threat of growing antibiotic resistance may affect those encouraging results.
Cempra Pharmaceuticals and Biovista have signed a research agreement to systematically identify and profile adverse event associations for members of the macrolide drug class.
- a slit in a tire to drain away surface water and improve traction.